close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 4 Next >
News headline image
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Highlighted in Forbes Article
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana to Participate in January Investor Meetings
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Host Investor Call
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today